Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Oxford Nanopore appoints Dr John Milton and Clive G. Brown

Abstract:
Oxford Nanopore Technologies Ltd ("Oxford Nanopore") today announces the appointment of Dr John Milton as Director of Nanopore Chemistry and Clive G. Brown as Director of Bioinformatics and IT.

Oxford Nanopore appoints Dr John Milton and Clive G. Brown

Oxford, UK | Posted on June 10th, 2008

Oxford Nanopore is developing nanopore technology into a molecular detection and analysis platform with a broad range of applications including DNA sequencing. Dr Milton and Clive Brown bring outstanding, relevant experience to their roles at the Company.

Dr Milton was previously Senior Director of Research at Solexa, a Cambridge University spin-out. At Solexa he was principal architect of the sequencing-by-synthesis chemistry that formed the basis of the Genome Analyzer, now a leading second generation DNA sequencing technology. His previous experience includes roles at GlaxoWellcome and Xenova.

Clive G. Brown joins Oxford Nanopore from the Wellcome Trust Sanger Institute (WTSI), Cambridge, UK. At the WTSI he played a key role in the adoption, operation and development of 'next generation' DNA sequencing platforms. WTSI has recently submitted hundreds of Gigabases of high quality data to the 1000 genomes project. Prior to this he was Director of Computational Biology & IT at Solexa.

"We are delighted to welcome John Milton and Clive Brown to our team," said Dr Gordon Sanghera, CEO of Oxford Nanopore. "The appointment of two senior executives with an exceptional track record in sequencing technology reflects the acceleration of our programme to deliver a nanopore-based, label-free, single molecule sequencing system. John and Clive bring not only great technical expertise but also a deep understanding of sequencing applications. This knowledge will help us to develop a sequencing system that truly meets the needs of researchers."

####

About Oxford Nanopore Technologies Ltd
Oxford Nanopore is developing nanopore technology, a revolutionary method of molecular detection and analysis with potential for DNA sequencing, diagnostics, drug development and defence applications. The company was founded on the science of Professor Hagan Bayley of the University of Oxford.

The Company's BASE™ technology is a system for DNA sequencing that employs nanopores to process, identify and record DNA bases in sequence. In contrast to current sequencing technologies, nanopores offer a potential method of directly sequencing DNA at single molecule resolution. This removes the need for amplification or labelling, and allows detection from an electrical signal rather than by fluorescence-based CCD imaging. In order to make a breakthrough in speed and cost, other competing technologies require step changes in optics, computation, and CCD camera technologies. Nanopores provide an alternative path to a step-change in the power and cost of DNA sequencing.

Recent interest in the “race for the $1000 genome" illustrates the needs for a sequencing technology that is affordable and powerful enough to enable an exponential increase in research and understanding of the genome. This knowledge will enable a new era in medicine, agriculture, energy, biodiversity, evolutionary biology, genealogy and many other fields.

The nanopore molecular detection system is powerful and versatile beyond its DNA sequencing potential. It can be adapted to detect a wide range of molecules, including other nucleic acids, proteins, small organic molecules and ionic species.

John Milton PhD, Director of Nanopore Chemistry

John followed his PhD in Organic Chemistry with positions at GlaxoWellcome and Xenova, where he specialised in designing new chemical systems that interact with the biological machinery of genetic processing. During his pharmaceutical career he delivered a number of novel therapeutic molecules into the clinic in the areas of HIV, virology, cancer and cancer related multidrug resistance. This included the HIV therapy Lamivudine (Epivir).

In 2001, John joined the Cambridge University spin-out Solexa, where he was principal architect of the novel sequencing-by-synthesis chemistry. As Senior Director of Research, he built and managed a team of 50 scientists, and took the technology through research, scale up, production, manufacturing and productisation for eventual commercial launch of the Genome Analyzer system in late 2006. From seed funding Solexa successfully raised over $150m before eventual sale to Illumina Inc for over $600m in early 2007.

Most recently, John has been closely involved with a number of biotech startups, looking to exploit the vast wealth of new human sequence data in the medical diagnostics field.

Clive G. Brown, Director of Bioinformatics & IT

Clive joined Oxford Nanopore Technologies from the Wellcome Trust Sanger Institute (Cambridge, UK) where he played a key role in the adoption and exploitation of 'next generation' DNA sequencing platforms, culminating in the submission of hundreds of Gigabases of high quality data to the 1000 genomes project.

Prior to this he was Director of Computational Biology & IT at Solexa, where he was integral to the development of the Genome Analyzer (GA). Clive's team built Solexa's high-performance computing infrastructure and supported all of the breakthrough science behind the GA's development. The group also provided the software tools, core algorithms, data and relationship building that enabled subsequent product adoption.

Clive has held various management and consulting positions at GlaxoWellcome, Oxford Glycosciences and other EU- and US-based organisations, where he has worked at the interface between computing and science, ranging from genetics to proteomics. He has also been responsible for several successful commercial data products and holds degrees in Genetics and Computational Biology from the University of York.

For more information, please click here

Contacts:
Dr Gordon Sanghera, CEO
Zoe McDougall, Communications
+44 (0)870 486 1966

Copyright © Oxford Nanopore Technologies Ltd

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Announcements

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Argon is not the 'dope' for metallic hydrogen March 24th, 2017

Promising results obtained with a new electrocatalyst that reduces the need for platinum: Researchers from Aalto University have succeeded in manufacturing electrocatalysts used for storing electric energy with one-hundredth of the amount of platinum that is usually needed March 24th, 2017

Artificial photosynthesis steps into the light: Rice University lab turns transition metals into practical catalyst for solar, other applications March 23rd, 2017

Tools

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Caught on camera -- chemical reactions 'filmed' at the single-molecule level March 22nd, 2017

CRMGroup in Belgium uses a Deben three point bending stage in the development of new steel & coated steel products for automotive and other industrial applications March 21st, 2017

Next-gen steel under the microscope March 18th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

Nanobiotechnology

Cryo-electron microscopy achieves unprecedented resolution using new computational methods March 25th, 2017

Nanobiotix: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma March 23rd, 2017

Nanoparticle paves the way for new triple negative breast cancer drug March 20th, 2017

Block copolymer micellization as a protection strategy for DNA origami March 17th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project